Regulation of gene expression by protein methylation
View Patent ↗The invention relates to the cDNA and deduced amino acid sequence of the Coactivator Associated arginine (R) Methyltransferase protein, CARM1. A method is described for the use CARM1 to regulate gene expression in vivo. CARM1 has also been used to methylate arginine residues of histones, synthetic peptides, and other proteins. A method to use CARM1 to screen for drugs that inhibit its methyltransferase activity is also described, as is a method to screen for drugs that modulate CARM1's interactions with other proteins.
1. A method for screening of molecules that modulate CARM1 regulated coactivator activity in a cell comprising:
expressing in said cell a p160 coactivator;
expressing in said cell a nuclear receptor-dependent reporter gene controlled by a transcription factor;
expressing in said cell a recombinant polynucleotide encoding CARM1 polypeptide that comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and having nuclear receptor-dependent coactivator activity;
and
comparing the expression levels of said reporter gene in said cell in the presence and absence of a modulating compound.
2. The method of claim 1 , wherein the p160 coactivator is selected from GRIP1, SRC-1 or p/CIP;
expressing in said cell a second coactivator with histone acetyltransferase activity selected from p300, CBP, p/CAF, or a second protein arginine methyltransferase selected from PRMT1, or PRMT3;
expressing in said cell a nuclear receptor gene, wherein said nuclear receptor gene is expressed at a level such that expression of said reporter gene is higher than in a cell not expressing either CARM1, a p160 coactivator, or either a second coactivator or a second protein arginine methyltransferase; and
comparing the expression levels of said reporter gene in said cell in the presence and absence of a modulating compound.
3. A method for extracellular screening for a molecule that inhibits CARM1 methyltransferase activity in a cell comprising incubating a first mixture of:
a candidate inhibitor molecule;
a purified or recombinant CARM1 polypeptide that comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and having methyltransferase activity;
a CARM1 substrate protein;
a labeled S-adenosylmethionine,
and separating the CARM1 substrate protein from the first mixture and measuring the amount of separated, labeled CARM1 substrate protein separated from the mixture and comparing to the amount of separated, labeled CARM1 substrate protein from an activity of CARM1 measured in the absence of the candidate inhibitor molecule.
4. The method of claim 3 , wherein the recombinant CARM1 polypeptide comprises SEQ ID NO: 2 and the CARM1 substrate protein is histone H3.
5. The method of claim 3 , further comprising incubating a second mixture of:
a recombinant or purified CARM1 polypeptide that comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and having methyltransferase activity;
a CARM1 substrate protein;
a labeled S-adenosylmethionine,
separating the CARM1 substrate protein from the second mixture and measuring the amount of separated, labeled CARM1 substrate protein separated from the second mixture; and
comparing the amount of separated, labeled CARM1 substrate protein labeled in the second mixture to the amount of separated, labeled CARM1 substrate protein labeled in the first mixture.
6. The method of claim 3 , wherein the presence of separated, labeled substrate protein indicates that the candidate molecule does not inhibit CARM1 activity.
7. The method of claim 3 , wherein the absence of separated, labeled substrate protein indicates that the candidate molecule does inhibit CARM1 activity.
8. The method of claim 4 , wherein the presence of separated, labeled substrate protein indicates that the candidate molecule does not inhibit CARM1 activity.
9. The method of claim 4 , wherein the absence of separated, labeled substrate protein indicates that the candidate molecule does inhibit CARM1 activity.
10. The method of claim 5 , further comprising providing a negative control which comprises incubating a third mixture of:
a recombinant CARM1 polypeptide that comprises an amino acid sequence of SEQ ID NO: 3;
a CARM1 substrate protein;
a labeled S-adenosylmethionine,
separating the CARM1 substrate protein from the third mixture and measuring the amount of separated, labeled CARM1 substrate protein separated from the third mixture; and
comparing the amount of separated, labeled CARM1 substrate protein labeled in the third mixture to the amount of separated, labeled CARM1 substrate protein labeled in the first mixture.
11. A method for extracellular screening for a molecule that inhibits CARM1 methyltransferase activity in a cell comprising incubating a mixture of:
a candidate inhibitor molecule;
a recombinant CARM1 polypeptide that comprises SEQ ID NO: 2 or an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and having methyltransferase activity;
a CARM1 substrate protein selected from histone H3 or histone H2a;
a labeled S-adenosylmethionine,
and separating the CARM1 substrate protein from the mixture and measuring the amount of separated, labeled CARM1 substrate protein separated from the mixture and comparing to the amount of separated, labeled CARM1 substrate protein from an activity of CARM1 measured in the absence of the candidate inhibitor molecule.
12. The method of claim 11 , wherein the recombinant CARM1 polypeptide comprises SEQ ID NO: 2.
13. The method of claim 11 or 12 , wherein the presence of separated, labeled substrate protein indicates that the candidate molecule does not inhibit CARM1 activity.
14. The method of claim 11 or 12 , wherein the absence of separated, labeled substrate protein indicates that the candidate molecule does inhibit CARM1 activity.